Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.
More Stories
Flutter Entertainment’s stock up 8% after FanDuel parent outlines growth plans and unveils $5 billion share buyback
FanDuel boosted its outlook for the size of the total addressable market in North America.
My wife and I immigrated to the U.S. with our son, 25. We have $45,000. Do we buy a house in California — or save our money?
“We are all naturalized citizens. We have a small savings of over $45,000 deposited in a high-yield savings account.”
Reddit extends machine-learning translation to 35 new countries, including Brazil and Spain
Social-media platform Reddit is rolling out machine-learning translation to a slew of new countries.
Why this holiday season, shoppers might finally be ready to buy fancier stuff
From Nov. 1, when holiday spending picks up in earnest, through Dec. 31, Adobe expects U.S. online sales of $240.8...
Target Hospitality’s stock tumbles 24% after buyout committee disbanded
Target Hospitality Corp.’s stock tumbled 24% early Wednesday, after the provider of modular housing said it has disbanded a special...
The 10-year Treasury yield is climbing after the Fed’s big rate cut. Why investors should be concerned.
The Federal Reserve is all about delivering a soft landing for the economy. Investors aren’t totally convinced.